Revenue came to $39 billion for the fiscal quarter ended in November, driven by higher prices for branded drugs and prescription volumes at the company’s U.S. retail pharmacy division.

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *